34 results about "Alanine transaminase" patented technology

The invention discloses a glutamine transaminase mutant with improved enzymatic activity, which belongs to the field of enzyme engineering. The site-specific mutagenesis is performed on glutamine transaminase, an amino acid residue close to an active site of the glutamine transaminase is changed, so that the catalytic efficiency of the glutamine transaminase is improved, and the enzymatic activityof the glutamine transaminase is further improved. Recombinant yarrowia lipolytica with improved enzymatic activity is established by the glutamine transaminase mutant, the enzymatic activity of theglutamine transaminase is improved by 1.45 times compared with an original strain, the enzymatic activity of the shake flask fermentation can reach 16.995U/mL, and the enzymatic activity of the fermenting tank fermentation can reach 59.85U/mL which is the highest fermentation value reported at present.

A novel alanine transaminase gene (ALT2) is isolated from human tissue. ALT2 specific polynucleotides, polypeptides, and antibodies are described. ALT2 is expressed predominately in liver, kidney, brain, muscle, and adipose tissue. ALT2 can be used to diagnose injury and diseases involving tissues expressing ALT2.

The invention relates to the technical field of biology and in particular relates to a method for constructing a hepatitis B virus (HBV) infected mouse model and application of the HBV infected mouse model. The invention provides a method for constructing a high-ALT (alanine transaminase) HBV infected mouse model. The method for constructing the HBV infected mouse model comprises the step of medicating HBV genome DNA plasmid to a Tlr2 gene-deficient mouse, so that the HBV infected mouse model is constructed. The mouse model provided by the invention is relatively simple to construct, relatively easy in technological means and low in construction cost; besides, the adopted HBV plasmid vector is non-toxic, can not induce immune response of the mouse and also can avoid serious immunodeficiency in a chimera mouse model, and the obtained HBV infected model has higher blood serum ALT level and obvious liver inflammation expression.

The invention discloses a method for quantitatively detecting alanine transaminase in a solution based on a copper nanocluster fluorescent probe, wherein a copper nanocluster with glutathione as a protective agent is used as a fluorescent probe, and the content of alanine transaminase in the solution is specifically detected through a fluorescence "off-on" mode. The label-free, highly sensitive and selective detection of alanine transaminase is achieved by adopting the fluorescence "off-on" mode. The method is simple and rapid, the specific detection of alanine transaminase can be realized, the detection linear range is wide, and the detection limit is low. The method in the invention has good detection sensitivity and selectivity and has good application prospects in disease detection, clinical application and other aspects.

The invention discloses a test card for the liver function and a preparation method thereof. The test card comprises an upper shell, a lower shell, a sample adding hole formed in the upper shell, an alanine transaminase detecting unit, a total bilirubin detecting unit and a glutamic oxalacetic transaminase detecting unit, wherein the alanine transaminase detecting unit, the total bilirubin detecting unit and the glutamic oxalacetic transaminase detecting unit are disposed between the upper shell and the lower shell. The alanine transaminase detecting unit, a total bilirubin detecting unit anda glutamic oxalacetic transaminase detecting unit comprise a bottom plate disposed at the upper end of the lower shell, lower shell detecting holes formed in the lower shell, bottom plate detecting holes formed in the bottom plate, a diffusion film disposed at the lower end of the upper shell and connected to the bottom plate, a whole blood separation layer disposed under the diffusion film and areaction layer disposed between the whole blood separation layer and the bottom plate detecting holes. The test card is matched with a dry biochemical analyzer for use, the operation is simple, the content of alanine transaminase, total bilirubin and glutamic oxalacetic transaminase can be detected rapidly and simultaneously without the need of a professional, and the detecting results are well matched with hospital detecting results.

The invention discloses a method for preparing DL-alanine and D-alanine. Fumaric acid and ammonia react through aspartase in a coupling reactor to synthesize L-aspartic acid; the synthesized L-aspartic acid reacts with L-aspartate dacarboxylase to obtain L-alanine; L-alanine undergoes racemization through alanine racemase to obtain DL-alanine; and DL-alanine concentrated mother liquor undergoes splitting through L-alanine aminotransferase in a fermentation cylinder so as to obtain D-alanine. Production of DL-alanine or D-alanine requires no extraction of intermediate products. The final product is obtained directly by one step. Thus, usage of sulfuric acid required for electroextraction of L-aspartic acid and the like, labor for each extraction process, energy consumption and production loss such as dissipation in actual production process are reduced. Meanwhile, DL-alanine mother liquor is comprehensively utilized for production of D-alanine, and overall yield and economic benefit are raised.

The invention relates to an Antrodia Camphorata cyclohexanone compound for protecting the liver, particularly 4-hydroxy-2,3-dimethoxy-6-methy-5[3,7,11- trimethyl-dodeca-2,6,10-trienyl]-cyclohex-2-enone separated from an Antrodia Camphorata extract and capable of effectively protecting the liver. The Antrodia Camphorata cyclohexanone compound is conducive to alleviating the injury of the liver tissue due to the chemical liver injury and the fiberization extent, and can reduce the concentrations of alanine aminotransferase (ALT) and aspartic acid (AST), increase the contents of glutathione peroxidase (GSHPx) and catalase (CAT) in the liver and reduce the injury of free radicals to liver cells so as to improve the oxidization resistance of the liver tissue and further protect the liver.

The invention discloses an application of methane injection in preparation of medicaments for treating ischemia-reperfusion injury, which comprises a preparation method of the methane injection. Animal experiments are performed on the methane injection, and the results prove that the methane injection can be used for obviously reducing the level of alanine transaminase, reducing liver injury and reducing hepatocyte apoptosis against a rat model with liver ischemia-reperfusion injury, so that the methane injection can be used for treating the liver ischemia-reperfusion injury. Thus, the methane injection disclosed by the invention can be used for preparing the medicaments for treating the ischemia-reperfusion injury.

The invention relates to application of a composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH), in particular to application of the composition of the micromolecular fucoidan and the fucoxanthin to preparation of the composition for improving the NASH. The composition can achieve the purpose of improving the NASH byimproving the fatty liver coefficient and blood biochemical parameters of serum alanine transaminase (ALT), ante cibum glucose (AC) and glycosylated heme (HbAlc).

The invention belongs to the technical field of microbial fermentation, and particularly relates to a method for preparing D-alanine by a microbial fermentation method. The method comprises the following steps: firstly, constructing a genetically engineered bacterium for producing D-alanine, taking corynebacterium glutamicum ATCC 13032 as a starting strain of the genetically engineered bacterium, and knocking out an alanine racemase gene alr and L-alanine transaminase alaT; allowing meso-diaminopimelate dehydrogenase coding gene to be subjected to overexpression; knocking out an iolR repressor protein gene and simultaneously performing genome integration expression on a glucokinase gene glk1; and integrating edd and eda genes from Escherichia coli to obtain the gene. The strain uses glucose as a substrate to produce D-type amino acid through a direct fermentation method, the cost is low, the technology is simple, and the yield of D-alanine in a 5L fermentation tank can reach 50-60g/L. Besides, efficient synthesis of the D-type amino acid by a fermentation method belongs to creative research, and by means of the method, the fermentation method can be infinitely expanded, and various D-type amino acids can be efficiently synthesized at low cost.

The invention relates to a production process of health wine, in particular to an aloe vera health care wine and a production process thereof. The production process includes: by weight part, subjecting aloe vera leaf pulp, smashed steamed sorghum rice and wheat distiller's yeast in a ratio of 1:10:3 to solid state fermentation firstly, then conducting liquid state secondary fermentation, and finally using purified water for blending to a required alcohol content. As alcohol can kill microorganisms, the aloe vera health care wine provided by the invention can keep stable quality, and has highinhibition effect on vegetative forms of bacteria, spores, fungi and viruses. Additionally, because of the adding of aloe, under the combined action of bradykinin enzyme, catalase, alanine transaminase and other enzymes, ethanol can undergo enzymolysis, chain scission and dehydrogenation, and be decomposed into acetaldehyde substances that cannot be absorbed by the human body, thereby greatly reducing the harm of ethanol to the human body. At the same time, the aloe vera has the effects of expelling toxin and maintaining beauty, activating the cardiovascular system, dredging blood capillaries,and killing bacteria.

The invention aims to solve the problem that a non-invasive diagnosis method is hardly available for confirming the hepatic pathological state of people with alanine transaminase (ALT) being less than two times of an upper normal limit in the prior art, and provides a system for predicting a liver inflammatory degree of a chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. The system comprises a detection module, an Inf-index1 calculation module and a liver inflammatory degree prediction module, wherein the detection module is used for detecting hepatitis B core antibody content, glutamic oxalacetic transaminase content and albumin content in serum of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit; the Inf-index1 calculation module is used for calculating Inf-index1 according to the hepatitis B core antibody content, the glutamic oxalacetic transaminase content and the albumin content; the liver inflammatory degree prediction module is used for predicting the liver inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. As proved by clinical test, the system has high prediction accuracy on the inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than the double upper normal limit, and a novel method is provided for clinical diagnosis.

The invention relates to the technical field of animal model construction, in particular to application of phosphorylated muramyl dipeptide for preparing a medicine capable of constructing fulminant liver injury animal model. D-galactosamine and the phosphorylated muramyl dipeptide are adopted for jointly constructing the fulminant liver injury animal model, an animal serum ALT (Alanine transaminase) level can be induced to sharply rise under a situation that a proper dosage is given, and hepatic cells can be protected from massive necrosis. Since an injury phenomenon happens in short time after injection, a determination result shows that the fulminant liver injury animal model is successfully constructed.

The invention relates to the field of pharmacy, discloses a new application of rotigotine in preparation of an acute liver injury resisting medicine, and particularly discloses an application of rotigotine in preparation of the acute liver injury resisting medicine. Rotigotine can reduce the levels of alanine transaminase (ALT) and glutamic oxalacetic transaminase (AST) in serum of mice with liverinjury induced by lipopolysaccharide (LPS)/D-Gal, reduce the concentration of TNF-alpha in serum of mice with acute liver injury, relieve pathological injury of liver tissues and reduce diffuse hemorrhage of the liver tissues. Pharmacological experiments prove that rotigotine has the effect of relieving acute liver injury, and a new prevention or treatment drug is provided for liver injury.

The invention discloses drunkenness-delaying liver protecting tablets and a preparation method thereof. The liver protecting tablets comprise 200-400 parts of Tulipa edulis bulb extract and 400-500 parts of a gastric mucosa protecting agent. The liver protecting tablets have the advantages that the Tulipa edulis bulb extract with colchicine removed and the gastric mucosa protecting agent are usedas main drugs, a protection film is formed in vivo by the drugs, activity of alanine transaminase (ALT) and aspartate amino transferase (AST), total antioxidant capacity (TEAC), activity of acetaldehyde dehydrogenase (ALDH), activity of glutathione peroxidase (GPx), activity of catalase (CAT), total SOD activity, content of reduced glutathione (GSH) and content of malonaldehyde (MDA) in vivo can be adjusted to slow down alcohol absorption while inhibiting excessive oxidative stress caused by alcohol, an endogenous antioxidation system is protected, and activity of ALDH is improved, so that efficacy of delaying drunkenness and improving alcoholic liver injury is realized.